MedTrace Logo

Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients

NCT04229121 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-01-18

No results posted yet for this study

Summary

Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation

Conditions

  • Advanced NSCLC
  • Circulating Tumor Cells
  • Circulating Tumor DNA

Interventions

OTHER

nonintervention

nonintervention

Sponsors & Collaborators

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Yayi He, MD,PHD · Shanghai Pulmonary Hospital, Tongji University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-15
Primary Completion
2020-06-15
Completion
2020-12-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04229121 on ClinicalTrials.gov